Skip to content

    Zota Health Care

    ZOTA
    Healthcare·5 Feb 2026
    Management Summary

    Zota Health Care reported robust top-line growth in Q3 FY26, with revenue nearly doubling and gross profit increasing over 113% YoY, driven by aggressive expansion of its Davaindia retail network. A successful INR 350 crore QIP provides capital for further growth. However, profitability metrics like EBITDA moderated due to front-loaded operating expenses and employee costs associated with a large pipeline of new stores, which management expects to normalize in the coming quarters.

    Highlights

    5
    • Consolidated revenue from operations grew 98.2% YoY to INR 14,295.14 lakhs in Q3FY26, driven by store additions and improved scale.

    • Consolidated Gross Profit increased 113.9% YoY to INR 8,617.82 lakhs, supported by operating leverage.

    • The Davaindia retail pharmacy network expanded by 276 new stores (231 COCO, 45 FOFO), bringing the total footprint to 2,331 stores as of December 31, 2025.

    • A INR 350 crore Qualified Institutional Placement (QIP) was successfully completed, strengthening the balance sheet and providing financial flexibility for growth initiatives.

    • Quarterly customer footfall increased to 49 lakhs in Q3FY26, up from 27 lakhs in Q3FY25, and Quarterly GMV nearly doubled YoY to INR 12,172 lakhs.

    Concerns

    3
    • Operating profit and consolidated EBITDA moderated to INR 127.58 lakhs for the quarter, primarily due to higher operating expenses linked to aggressive network expansion.

    • Employee costs increased significantly from INR 38 crore in Q2 to INR 52 crore in Q3, mainly attributed to non-live/under process stores and front-loaded store additions.

    • Near-term margins have been impacted by expansion-led investments, though management expects these costs to be transitory and normalize in the next 1-2 quarters.

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Revenue14,295.14 lakhs+98.2%YoY
    2. 02Consolidated Gross Profit8,617.82 lakhs+113.9%YoY
    3. 03Consolidated EBITDA127.58 lakhs
    4. 04Employee Costs5,200 lakhs
    5. 05Quarterly GMV12,172 lakhs

    Segment breakdown

    Davaindia
    80% Revenue Contribution
    Domestic Sales
    11% Revenue Contribution
    Export Sales
    6% Revenue Contribution
    Everyday Herbal Group
    2% Revenue Contribution
    List

    Capital allocation

    4
    high confidence
    CategoryHeadline
    M&A

    Curexis

    acquisition · closed

    M&A

    KMHP Ventures Limited

    Other · announced · Consideration ₹10 lakh

    M&A

    Davaindia Health Mart Limited (DIHML)

    Other · announced

    Liquidity

    Cash ₹350 crores

    QIP proceeds utilized to accelerate COCO rollout, support working capital requirements, and meet general corporate purposes.

    Guidance & targets

    6
    CategoryTargetPriority
    Network Expansion
    Davaindia Stores
    5,000 stores
    High
    Network Expansion
    COCO Store Additions (Annual Target)
    800 stores
    High
    Network Expansion
    COCO Store Additions (Quarterly Run-Rate)
    200-250 stores
    High
    Profitability
    Gross Margin
    70%
    Medium
    Profitability
    Company Level EBITDA Margin (all stores mature, no new stores)
    17-20%
    Medium
    Cost Management
    Employee Costs Normalization
    Normalize
    High

    Employee Cost Normalization

    next one to two quarters
    CurrentINR 52 crore (Q3FY26)
    TargetNormalization and stabilization

    Why it matters

    The significant increase in employee costs impacted Q3 EBITDA; its normalization is key for margin recovery and improved profitability.

    So overall, the increase is primarily driven by higher salary costs related to non-live stores and the aggressive expansion undertaken during the last quarter. Going forward, we expect this to normalize and stabilize over the next one to two quarters.

    How to verify

    key_financials.metrics[label='Employee Costs']

    Risks & concerns

    3
    RiskSeverity

    Near-term margin compression due to expansion-led investments

    Higher operating expenses and pre-opening costs for new stores are impacting near-term margins, but these costs are expected to be transitory and normalize in 1-2 quarters.Management acknowledged

    medium

    Significant increase in employee costs

    Employee costs rose from INR 38 crore in Q2 to INR 52 crore in Q3, primarily due to costs associated with ~650 stores (opened and in pipeline) that are not yet fully operational. Normalization is expected in 1-2 quarters.Management acknowledged

    medium

    GMV reporting lags revenue recognition for FOFO stores

    GMV reporting is dependent on franchisee invoicing, and sell-through may lag goods supplied, leading to a narrowed gap between revenue and GMV. Limited control over franchisee invoicing can also affect full capture of sales.Management acknowledged

    low

    Q&A highlights

    8

    “So overall, the increase is primarily driven by higher salary costs related to non-live stores and the aggressive expansion undertaken during the last quarter. Going forward, we expect this to normalize and stabilize over the next one to two quarters.”

    Addresses the significant increase in employee costs and provides a timeline for its expected normalization, crucial for margin recovery.

    asked by Chintan Sheth

    3 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Zota Health Care reported a consolidated revenue from operations of INR 14,295.14 lakhs in Q3FY26, representing a strong year-on-year growth of 98.2% compared to INR 7,212.38 lakhs in Q3FY25. Consolidated Gross Profit also saw a significant increase of 113.9% YoY, reaching INR 8,617.82 lakhs from INR 4,029.15 lakhs in the prior year. However, operating profit and consolidated EBITDA moderated to INR 127.58 lakhs for the quarter, primarily due to higher operating expenses linked to aggressive network expansion, including pre-opening costs for approximately 400 stores under development.

    02

    Davaindia Network Expansion and Strategic Initiatives

    The company continued its aggressive expansion of the Davaindia retail pharmacy network, adding 276 new stores in Q3FY26, comprising 231 COCO and 45 FOFO stores. This brought the total Davaindia footprint to 2,331 stores as of December 31, 2025. The medium to long-term objective is to cross 5,000 Davaindia stores across India by March 2029. Quarterly customer footfall increased to 49 lakhs in Q3FY26 from 27 lakhs in Q3FY25, and Quarterly GMV nearly doubled YoY to INR 12,172 lakhs, reflecting improved store productivity and network scale.

    03

    Capital Raising and M&A Activities

    A key milestone during the quarter was the successful completion of a INR 350 crore Qualified Institutional Placement (QIP), with proceeds primarily utilized for accelerating COCO store rollout, working capital, and general corporate purposes. The company also incorporated a new wholly owned subsidiary, KMHP Ventures Limited, with an initial paid-up capital of INR 10 lakh, to engage in marketing and trading of pharmaceutical products. Furthermore, Zota acquired a 100% equity stake in Curexis, a retail pharmacy platform operating under the brand 'SKIA,' to expand its footprint in the retail generic and specialty pharmacy segment.

    04

    Margin Dynamics and Cost Management

    While gross margins have improved to 66-67% in Q3FY26, up from 55% YoY, operating profit and EBITDA moderated due to higher operating expenses linked to network expansion. Employee costs increased from INR 38 crore in Q2 to INR 52 crore in Q3, primarily due to costs associated with approximately 650 stores (231 opened and 400+ in pipeline) that are not yet fully operational. Management expects these expansion-led costs to be transitory📎, with normalization and improved operating leverage anticipated in the next 1-2 quarters as newly added stores mature.

    05

    Impact of GST Reduction on GMV and Store Performance

    The reported GMV in Q3FY26 was affected by a 5.15% GST impact, as the GST rate for certain products was reduced from 12% to 5%, directly impacting MRPs and reported GMV. Management clarified that when adjusted to the old GST structure, the underlying growth trend remains intact, with older cohorts experiencing 15-20% annual growth. Despite the addition of many new stores with lower initial wallet spends, the average wallet spend remained stable, indicating underlying improvement in customer purchasing behavior.

    06

    Marketing and Brand Building Initiatives

    Zota Health Care has initiated extensive Below-The-Line (BTL) campaigns featuring brand ambassadors Sunil Shetty and MS Dhoni. TVC shoots with Sunil Shetty have been completed and are being aired in cinemas and taxis, while MS Dhoni's TVC is expected to be ready in two weeks. Television broadcasts featuring the brand ambassadors have also commenced, with more TVCs planned for the coming months. Management emphasized a judicious approach to marketing spend, aligning it directly with organizational growth and COCO store expansion rather than adhering to fixed budgets.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.